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ABSTRACT

Babar, Aditya. M.S., Purdue University, May 2016. Biochemical Studies of a
Deubiquitinating Enzyme in Chlamydia Trachomatis. Major Professor: Chittaranjan
Das.

Chlamydia Trachomatis (C. trachomatis), a gram negative, obligate intracellular
bacterium, is implicated in a variety of diseases including sexually transmitted urogenital
infection, as well as ocular infection. Reliance on the host cell for its survival and
propagation causes the bacterium to release various bacterial effector proteins to
manipulate its host cell processes. Two of these factors which may aid in the bacterium’s
survival, C. trachomatis deubiquitinase 1 (ChlaDub1) and C. trachomatis deubiquitinase 2
(ChlaDub2) are cysteine proteases which have been previously shown to exhibit
deubiquitinating and deneddylating activity. In this study, constructs of ChlaDub2 were
cloned, purified, and subjected to enzymatic assays to probe its activity. Using diubiquitin
of defined linkage type, it was demonstrated that ChlaDub2 shows a preference for Lys-63
linked diubiquitin over Lys-48 linked diubiquitin, albeit at a reduced rate with an increased
enzyme concentration. Additional biochemical assays were carried out with
polyubiquitinated GFP substrate that demonstrated ChlaDub2’s activity was more
enhanced at a lower enzyme concentration and reaction time. As the polyubiquitinated GFP
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would contain a heterogenous array of different linked polyubiquitin chains with mainly a
population of Lys-63 linked chains, insight is gained that ChlaDub2 may potentially prefer
longer length polyubiquitin. These results potentially point towards the physiological role
ChlaDub2 plays in the cell by protecting the C. trachomatis vacuole from Lys-63 induced
lysosomal degradation. Additionally, crystallographic studies were performed and
diffraction and a dataset were obtained; however, at the time, the structure could not be
phased.
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CHAPTER ONE. INTRODUCTION

1.1 Ubiquitination
Ubiquitin is an 8.5 kildalton protein which is used to covalently modify proteins
in order to signal for a variety of cellular processes.1 The ligation of ubiquitin to proteins,
referred to in the literature as ubiquitination, is a reversible post-translation modification
similar to other signaling events such as SUMOylation, adenylation, and
phosphorylation. The residues of ubiquitin are conserved across eukaryotic organisms,
differing only at three positions.1 The core structural feature of ubiquitin is reflective of a
beta-grasp fold (also known as an ubiquitin-like fold) which is comprised of an alphahelix surrounded by five beta-sheets.2 Ubiquitin contains seven lysine residues and a Nterminal methionine that can be attached to a substrate protein directly or be involved in
polyubiquitination (multiple ubiquitin monomers being covalently ligated together)
(Figure 1.1).3
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Figure 1.1 Ubiquitin protein structure with lysine residues highlighted in green. PDB ID:
1UBQ

The chemistry behind the mechanism of ubiquitination is an elegant process that
involves three enzymes: an E1 activating enzyme, an E2 conjugating enzyme, and an E3
ligase. In the human genome there exists 2 E1 molecules, roughly 38 E2s, and a range of
600-1000 E3 enzymes.4 In ubiquitination, the terminal glycine (76th residue) on ubiquitin
forms an isopeptide bond with the epsilon amino group on a lysine of a substrate protein,
as opposed to a canonical peptide bond.5 Ubiquitination begins by the E1 enzyme binding
to ubiquitin through an ATP-dependent step.1 The E1 first forms an adenylate with an
AMP molecule attached, followed by the ubiquitin being transferred to the active site
cysteine. Due to binding the ubiquitin (thiol-ester formation) and priming its C-terminus
for nucleophilic attack, the E1 is for this reason referred to as the ubiquitin activating
enzyme. The second step involves the ubiquitin being transferred to the active site
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cysteine residue of an E2 enzyme and further being carried along the ubiquitination
mechanism as a thiol-ester.1 The third step involves the E3 ligase which mediates the
transfer of the ubiquitin from the E2 enzyme to the lysine residue on ubiquitin’s
substrate.4 E3’s can either be really interesting new gene (RING) domain ligases or
homologous to the E6AP carboxyl terminus (HECT) domain ligase which differ in their
mechanism of ligating ubiquitin on a target protein.4,6

Figure 1.2 Ubiquitination diagram depicting cascade of E1, E2, and E3 enzymes
with a generic substrate protein. Bottom panel depicts removal of ubiquitin on proteins
with deubiquitinating enzymes (DUBs)

In addition to one ubiquitin molecule being covalently attached to a target protein
(monoubiquitination), proteins can also have multiple ubiquitin chains attached to them
which is referred to as polyubiquitination. Ubiquitin chains can be linked through either
its seven lysine residues (Lysine 6, 11, 27, 29, 33, 48, 63) or through its N-terminal
methionine. These ubiquitin chain linkages reflect various architectures which in turn
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reflect the specificity for certain chain types by deubiquitinating enzymes depending on
the biological context the deubiquitinating enzyme is acting within (Figure 1.3).2

Figure 1.3 Different modes of ubiquitination. Red squares represent substrate
protein and blue circles indicate ubiquitin. Lys-11, 48, 63, and Met-1 linked
ubiquitination biological functions are listed. Lys-6, 27, 29, 33 are not listed due to their
unknown biological function in cellular context

Additionally, different linkages that polyubiquitinate a substrate can signal for different
cellular fates.7 Lysine-63-linked polyubiquitination can signal for lysosomal degradation,
DNA repair, and nuclear factor-κB (NF-κB) signaling, while lysine 48-linked
polyubiquitination leads to protein degradation by the 26S proteasome.8,9 Lysine-11
linked polyubiquitination has been implicated for both protein degradation pathway as
well as being involved in regulation of the cell cycle.10,11 The biological role that
polyubiquitin linkages with Lys-6, 27, 29, and 33 have not been elucidated to date.11
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Furthermore, there exist other ubiquitin-like molecules that are also involved in
cell signaling events. These ubiquitin-like molecules include interferon-stimulated gene
15 (ISG15), neural precursor cell expressed, developmentally down-regulated 8
(NEDD8), and small ubiquitin-like modified (SUMO).12-14 These proteins are divergent
in their cellular biological function compared to ubiquitin; however, they do share a
similar three-dimensional folding pattern with ubiquitin .15

1.2 Deubiquitination
Deubiquitinases (DUBs) are enzymes that cleave ubiquitin from substrate
proteins, thus rendering ubiquitination a reversible process. Their biological function is
essential, as DUB dysfunction has been linked to various diseases such as Parkinson’s
disease and microcephaly-capillary malformation syndrome.16,17 The human genome
contains around 79 DUBs which are either cysteine proteases or zinc metalloproteases.18
The cysteine proteases consist of ubiquitin-specific proteases (USPs), ovarian tumor
proteases (OTUs), ubiquitin C-terminal hydrolases (UCHs), and Josephins.18 As the name
implies, cysteine protease DUBs contain a catalytic triad consisting of a catalytic cysteine
alongside a histidine and either an aspartic acid, asparagine, or a glutamic acid residue to
carry out its enzymatic activity on isopeptide bonds. The JAB1/MPN/MOV34 (JAMM)
class of DUBs, known as JAMM metalloproteases, contain zinc atoms in their active sites
that are directly involved in their catalytic deubiquitinating activity, as well as some that
contain zinc atoms that also contribute to their structural integrity.18
DUBs contain various domains that facilitate binding to ubiquitin. Specifically,
some of these domains tinclude ubiquitin-associated (UBA) domain, ubiquitin-interacting
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motif, and the zinc-finger ubiquitin-specific protease (ZnF-UBP) domain, which have
been confirmed by crystallographic studies.18 Two structural features on ubiquitin helps
facilitate binding to DUBs. One of these structural features is an N-terminal beta-hairpin
loop while the other is a hydrophobic region on the surface of ubiquitin known as the
isoleucine 44 patch.18 Canonically, this hydrophobic patch is used with many DUBs;
however other sites of binding with ubiquitin, such as with the bacterial DUB, SdeA,
have been demonstrated.19 Additionally, DUBs recognize and bind the C-terminal tail of
ubiquitin which contains an Leu-Arg-Gly-Gly motif and subsequently cleaves ubiquitin
off between the terminal Gly residues.18 DUBs can either cleave polyubiquitin chains in
an exo manner by cleaving ubiquitin from the end of the polyubiquitin chain, in an endo
manner by cleaving within the polyubiquitin chain resulting in two larger chains, or in an
en bloc manner by cleaving an entire polyubiquitin chain off the substrate protein.20

1.3 Chlamydia Trachomatis

1.3.1 Life Cycle of Chlamydia Trachomatis
Chlamydia trachomatis (C. trachomatis) is a gram negative, obligate (thus relying
on the host cell for its survival) intracellular bacterium that is a leading cause of
worldwide sexually transmitted genitourinary.21 Additionally, C. trachomatis is also
responsible for cases of ocular, as well as pulmonary infection.22 Packaged in a vesicular
body, C. trachomatis establishes a replicative niche that allows it to infect a eukaryotic
host cell as an elementary body, reproduce and mature into a reticulate body, and finally
be released out of the cell for continued infection.23 Furthermore, C. trachomatis
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elementary bodies possess a type-III secretion system consisting of a biological
machinery that consists of greater than 20 proteins that carry out their biological function
during the infectious lifecycle to release bacterial effector proteins which aid in their
survival.23-25

1.3.2 Chlamydia Trachomatis Deubiquitinating Enzymes
While it is well established that the ubiquitination system is inherent to eukaryotic
cells and not to prokaryotic cells, interestingly enough, C. trachomatis developed its own
deubiquitinating enzymes that would aid in facilitating its survival and evading the host
cell’s immune response, herein referred to as ChlaDub1 and ChlaDub2.26 Other bacterial
DUBS have also been reported and studied such as SdeA from Legionella pneumophila,
ElaD from Escherichia coli, and SsEL from Salmonella.19, 27,28 Through sequence
alignment, it was determined that these bacterial DUBs are variable in their sequences,
though the cysteine protease catalytic triad is conserved throughout. ChlaDub1 and
ChlaDub2 both possess a transmembrane domain through sequence similarity and contain
a conserved cysteine protease catalytic triad. However, the two proteins differ in their
sequence in that ChlaDub1 contains an insertion with multiple prolines (Figure 1.4). The
first paper that characterized C. trachomatis deubiquitinating enzymes yielded
confirmation that C. trachomatis did indeed have two enzymes that functioned as
DUBs.24 The study that was carried out tested the deubiquitination as well as
deneddylation activity of both proteins using ubiquitin and NEDD8 substrates covalently
linked to a fluorogenic molecule, AMC (7-amino-4-methylcoumarin). Additionally, the
use of suicide probes that would covalently link in the active site of ChlaDub1 and
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ChlaDub2 were employed to determine that the DUBs were cysteine proteases.
Furthermore, another group demonstrated that ChlaDub1’s biological relevance included
downregulation of nuclear-factor-κB signaling.29 Specifically, it was demonstrated that
ChlaDub1 lead to deubiquitination of IκBα, thus inhibiting its degradation and
subsequent NF-κB signaling
Thus, for this thesis, ChlaDub2 was cloned in various constructs, the protein was
expressed and purified, its biochemical activity was probed, and crystallization studies
were undertaken to further characterize the enzyme.
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Figure 1.4 Domain diagram and sequence alignment of ChlaDub1 and ChlaDub2. (A)
Yellow box labeled ‘TM’ indicates purported transmembrane domain, purple box labeled
“PP” represents polyproline insertion, and red box indicates DUB domain. (B) Sequence
alignment of ChlaDub1 and ChlaDub2 with conserved catalytic residues marked with
asterisk
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CHAPTER TWO. MATERIALS AND METHODS

2.1 Cloning and Mutagenesis

2.1.1 Cloning of Chlamydia Trachomatis Deubiquitinase 2 Constructs
The first Chlamydia trachomatis deubiquitinase 2 (ChlaDub2) construct, ChlaDub2
58-339 (ChlaDub2 Δ58), was cloned by first designing the forward and reverse primers
using Bioedit software to visualize the sequence. DNA oligomers were subsequently
procured from Sigma Aldrich. The restriction sites chosen for the cloning were Xho1 for
the forward primer and Not1 for the reverse primer (Figure 2.1).

Figure 2.1 Forward and Reverse primers of ChlaDub2 Δ58

The intended vector for the cloning of the ChlaDub constructs was pGEX-6P-1, an
ampicillin-resistant plasmid which allows for a Glutathione S-transferase (GST) fusion
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tag to be covalently attached to the N-terminus of the inserted protein upon successful
cloning and protein expression. A polymerase chain reaction (PCR) was set up to
amplify the desired length of ChlaDub2 Δ58 DNA using the following volumes of
reagents: 16 µL Milli-Q H2O, 2 µL ChlaDub2 full length template DNA, 1 µL ChlaDub2
Δ58 forward primer, and 1 µL ChlaDub2 Δ58 reverse primer all inserted into a PCR premix tube (Bioneer). The thermocycler (BioRad) PCR program was set using the
following program: 5 minute initial denaturation step at 95°C, followed by a 1 minute
denaturation step at 95°C, a 1 minute annealing step set at 62°C, and a 2 minute
elongation step carried out at 72°C. After the initial 5 minute denaturation period, the
program was set to carry out 25 cycles of amplification. Once the PCR reaction finished,
the reaction product was then visualized on a DNA agarose gel containing ethidium
bromide. The PCR product was then purified using a PCR purification kit (Qiagen) and
then subjected to restriction digest using the restriction sites, Xho1 and Not1, as indicated
above. The restriction digest was set up as follows: 15 µL purified ChlaDub2 Δ58 PCR
product was pipetted into a homemade 35 µL restriction digest Mastermix (38.5 µL
Milli-Q H2O, 7 µL New England Biolabs Buffer 3.0, 0.7 µL bovine serum albumin
(BSA), 1.4 µL Xho1, 1.4 µL Not1). The digest was allowed to incubate at 37°C for four
hours. After the four hour period, the double digest mixture was purified using a PCR
purification kit (Qiagen). In a separate tube, empty PGex-6P-1 vector was also subjected
at the same time to a restriction digest for four hours with Xho1 and Not1, followed by
adding 1 µL of calf intestine phosphatase (CIP) and allowed to incubate for an additional
two hours. The reason for CIP treatment is to remove the 5’ phosphate groups present on
the vector DNA and thus preventing the possibility of the empty vector reclosing on itself
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during the ligation step of the cloning protocol. After both the ChlaDub2 Δ58 PCR
product and empty pGEX-6P-1 vector were purified after restriction digest and CIP’ing, a
ligation was set up in the following manner: 6 µL digested ChlaDub2 Δ58, 1 µL digested
pGEX-6P-1 vector, 0.5 µL T4 Ligase, 1 µL T4 Ligase Buffer (New England Biolabs),
and 1.5 µL Milli-Q H2O. A parallel control ligation was also set up as such: 1 µL
digested pGEX-6P-1 vector, 0.5 µL T4 Ligase, 1 µL T4 Ligase Buffer, and 7.5 µL MilliQ H2O. The ligation and control ligation were incubated at 16°C overnight and then
transformed into Escherichia coli (E. coli) DH5-α cells and plated on lysogeny broth
(LB) Agar plates containing ampicillin. The plates were incubated at 37°C for 16 hours.
Two colonies were picked up using a micropipette tip and put into two separate overnight
cultures containing 5 mL LB media and 5 µL ampicillin (100 µg/µL). The cultures were
then spun down the next morning and were prepared using a Miniprep kit (Qiagen). The
miniprepped DNA samples from different colonies were then subjected to restriction
digestion using the same two enzymes, Xho1 and Not1, to confirm that the colonies
contained the ChlaDub2 Δ58 insert (Figure 2.2). The first colony indicated that the vector
was empty, while the second colony indicated successful ligation of the ChlaDub2 Δ58
insert.
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Figure 2.2 Cloning of ChlaDub2 Δ58. (A) Confirmation of PCR product of ChlaDub2
Δ58. (B) Restriction digest test of two colonies

ChlaDub2 Δ93 (residues 93-339) was cloned and confirmed using the same methods
described above as for ChlaDub2 Δ58 (Appendix I). ChlaDub2 Δ140 (residues 140-339)
was also cloned in the same manner; however, the confirmation of successful cloning was
carried out using colony PCR method. A PCR reaction was set up by pipetting up and
down a colony grown on the Amp mutagenesis plate and in a PCR premix tube (Bioneer)
with the following amounts of reagents added: 16 μL Milli-Q H2O and 1 μL of ChlaDub2
Δ140 forward and reverse primer. The PCR reaction program was the same as the initial
program used for mutagenesis. The confirmation of successful cloning was imaged on a
DNA agarose gel by seeing a DNA band at the correct approximate kilobase marker (0.6
kilobases) (Appendix I).
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2.1.2 Mutagenesis of Chlamydia Trachomatis Deubiquitinase 2
Since ChlaDub2 contains a catalytic triad consisting of histidine 203 (H203),
aspartic acid 220 (D220), and cysteine 282 (C282), primers were designed for the
following three mutants: H203A, D220N, and C282A. The PCR reaction was carried out
by mixing 16 μL Milli-Q H2O, 2 μL ChlaDub2 Δ58 template DNA, and 1 μL of the
forward and reverse primer respectively into a PCR pre-mix tube (Bioneer). The PCR
program was set up with a 5 minute initial denaturation step (95°C), followed by a 25
cycle reaction that had a 30 second denaturation step (95°C), 30 second annealing step
(55°C), and a 90 second elongation step (72°C). The final elongation step was set for 10
minutes. After the PCR was finished, 1 μL of Dpn1 enzyme was added to each PCR
reaction and incubated for 2.5 hours in a 37°C water bath. The reactions were then
transformed into dh5-α E. coli cells and plated on agar LB plates containing ampicillin.
After 20 hours, 2 colonies were picked from each plate and sent for sequencing at
Purdue’s Low Throughput Sequencing facility.

2.2 Protein Purification

2.2.1 ChlaDub2 Construct Protein Expression and Solubility Confirmation
The successful cloning of ChlaDub2 Δ58 was further continued by transforming
the ChlaDub2 Δ58 DNA into E. coli Rosetta cells. After transforming the cells and
plating on LB Agar containing ampicillin, the colonies were allowed to grow for 16 hours
at 37°C. A colony was picked up using a micropipette tip and deposited in a culture tube
containing 3 ml of LB media and 3 µL of ampicillin and allowed to incubate in a 37°C
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shaker overnight. The next morning two culture tubes were labeled – ‘Uninduced’ and
‘Induced’ – and were set up as follows: 3 ml LB media, 3 µl ampicillin, and 50 µL of the
overnight starter culture. After four hours in the 37°C shaker, protein expression was
induced in the tube labeled ‘Induced’ by adding 3 µL Isopropyl β-D-1thiogalactopyranoside (IPTG) and lowering the temperature to 18°C. Additionally,
during the same time period, 1 ml of the cell culture in the tube labeled ‘Uninduced’ was
pipetted into a microcentrifuge tube containing 1 ml 20 percent glycerol. This glycerol
stock was then flash frozen with nitrogen and stored at -80°C and used for future large
scale protein purification. After shaking at 18°C overnight, the tubes were centrifuged
and the cell pellets were resuspended in 600 µl 1X Phosphate Buffer-Saline containing
400 mM potassium chloride (KCl). The cell pellet resuspension in the ‘Induced’ tube was
then sonicated to lyse the cells to check the solubility of the protein in addition to its
expression. After taking a sample of the induced cells lysate, the culture was spun down
in a microcentrifuge. Samples from the ‘Uninduced’ tube, ‘Induced’ tube lysate, and
‘Induced’ tube supernatant were run on a sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) gel to check for protein expression and solubility (Figure
2.3).

19

Figure 2.3 Expression and solubility test of ChlaDub2 Δ58. M denotes the marker, U
denotes uninduced cells, IL denotes induced cells lysate, and IS denotes induced cells
supernatant

The other ChlaDub2 constructs used in this study including ChlaDub2 full-length,
ChlaDub2 Δ93 and ChlaDub2 Δ140, were confirmed in the same manner as described
above for ChlaDub2 Δ58. The ChlaDub2 mutants, Asp220Asn and Cys282Ala, were also
checked for expression and solubility in the same manner.
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2.2.2 Large Scale Protein Purification of ChlaDub2 Constructs
ChlaDub2 Δ58 was purified using GST-affinity tag purification methods (Figure
2.5). The purification began by inoculating 100 ml of LB media with a scraping of the
respective glycerol stock and 100 μl ampicillin. The starter culture was shaken overnight
in a 37° C shake. The next day, six 1 liter flasks of LB media were inoculated with 7 ml
of the ChlaDub2 Δ58 starter culture with addition of 1 ml of ampicillin and shaken at
37°C until reaching an optical density value (measured at 600 nm) of 0.4-0.6. Once the
appropriate optical density was reached, cells were induced with 300 μM IPTG and the
protein was expressed overnight at 18° C. Cells were harvested the next morning at 7000
RPM, followed by resuspension in 20 ml of 1X PBS with 400 mM KCl. Prior to French
pressing the cells, lysozyme was added to the resuspended cells and incubated on ice for
30 minutes. After 4 rounds of French press, the lysate was ultracentrifuged for 1 hour at
100,000 x g. Due to ChlaDub2 Δ58 containing an N-terminal GST-fusion tag, a
glutathione-Sepharose column (GE Biosciences) was employed to carry out the protein
purification. During the ultracentifugation step, the glutathione-Sepharose column was
equilibrated with 120 ml of 1X PBS containing 400 mM KCl. The supernatant resulting
from ultracentrifugation was loaded onto the column and the flow-through was collected
at 1 ml/minute. The glutathione-Sepharose beads were then washed with 120 ml of the
resuspension buffer, followed by elution with reduced glutathione. The GST tag was
cleaved using Prescission Protease (GE Biosciences) and dialyzed overnight to exchange
out the reduced glutathione present in the elution buffer. This results in a cloning artifact
on the N-terminus of the protein due to the restriction sites that were chosen for cloning.
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After dialysis, the cleaved protein was passed over the affinity to column to subtract
cleaved GST.

Figure 2.4 Large scale purification of ChlaDub2 Δ58. (A) M denotes marker, F1-F6
denotes each 1 liter flask confirming induction of the GST-tagged ChlaDub2 Δ58. (B)
Sup denotes supernatant after ultracentrifugation, FT denotes flow-through, W denotes
wash, Elu denotes elution, AD denotes after dialysis, and Sub denotes subtraction

The protein was further purified using size-exclusion chromatography in a buffer
containing 50 mM Tris-HCl (pH 7.6), 50 mM NaCl, and 1 mM DTT on a S75 Superdex
column (GE Biosciences). The fractions were run on a gel and the fractions
corresponding to the correct molecular weight (B11-C5) were concentrated down to 800
µl for final concentration of 203.3 μM (Figure 2.5). 50 μl aliquots were flash frozen and
stored at -80° C.
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Figure 2.6 SDS-PAGE gel of fractions run on size-exclusion column. L denotes the
concentrated down sample run on the column, M denotes marker, B3-C5 denotes the
samples run from the fraction collector

2.3 Synthesis of a Functionalized Ubiquitin Probe

2.3.1 Purification of Ubiquitin-MESNa
Ubiquitin-MESNa (mercaptoethane sulfonate), a modified ubiquitin molecule
(residues 1-75) is the precursor to making N-terminal functionalized ubiquitin probes
(Figure 2.7).1,2 Ubiquitin-MESNa was expressed in Rosetta E. coli cells in PTXB-1
vector by inoculating six 1 L culture flasks with an overnight culture made the previous
night containing 100 mL LB media, a scraping of the glycerol stock, and antibiotic. Cells
were grown in a 37°C shaker to an optical density (measured at 600 nm) of 0.6,
inoculated with 300 nM IPTG, and grown for 16 hours at 18°C. Cells were then
harvested, resuspended in column buffer, lysed using French Press, and then
ultracentrifuged at 100,000 x g. The supernatant was then poured into a column
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containing chitin beads which was stored in a 4°C cold room. After the flow-through was
collected, the column was then washed with column buffer. To release the Ub-MESNa
from the intein group, buffer containing 2-mercaptoethane sulfonate (MESNa) to induce
trans-thiol esterification was poured into the column and the reaction proceeded
overnight in the column. After overnight cleavage, the protein was concentrated down to
3 mL and aliquoted into 1.5 mL microcentrifuge tubes.

Figure 2.7 Schematic representation of Ub-MESNa purification
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2.3.2 Synthesis of Ubiquitin-Propargylamide
To synthesize the functionalized ubiquitin probe, ubiquitin-propargylamide, 1.5
mL of Ub-MESNa was reacted with 1 mL of propargylamine in 9 mL of 500 mM sodium
carbonate buffer pH 8.3 After the reaction was allowed to proceed overnight, the
ubiquitin-propargyl was quenched and dialyzed into column buffer A (50 mM sodium
acetate pH 4.5). After one 6 hour dialysis followed by an overnight dialysis, the
ubiquitin-propargyl was loaded onto a Mono S column (GE Biosciences). The ubiquitinpropargyl was eluted off the column with a gradient of column buffer B (50 mM sodium
acetate pH 4.5 and 1 M sodium chloride) over 45 column volumes. The fractions
collected off the Mono S column were tested for reactivity with a cysteine protease, GSTtagged ubiquitin carboxy-terminal hydrolase L3 (Figure 2.8).4 Reactive fractions A12-B6
were collected and concentrated down to two mL. Fraction B6 is an anomaly on the gel
due to an undiluted sample of GST-tagged ubiquitin carboxy-terminal hydrolase L3,
rather than a 1/50 dilution being reacted with fraction B3.

Figure 2.8 Mono S chromatogram and corresponding SDS-PAGE reactive fraction
gel. L denotes GST-ubiquitin-carboxy terminal hydrolase L3 control, M denotes
marker, A7-B6 denotes reactive fractions collected off the Mono S column reacted
with enzyme
26
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2.4 Biochemical Assays of ChlaDub2

2.4.1 Ubiquitin-Propargylamide Reactivity Assay
40 uM of ChlaDub2 Δ58, ChlaDub2 Δ93, ChlaDub2 D220N, and ChlaDub2
C282A were reacted with excess ubiquitin-propargyl in Tris pH 8 buffer. After letting the
reaction proceed overnight, the reactions were quenched and visualized on an SDSPAGE gel.

2.4.2 Diubiquitin Cleavage Assay
Diubiquitin cleavage assays were carried out using various ChlaDub2 constructs
and mutants. The reactions were run by incubating a ChlaDub2 construct (concentration
s cranging from 50 nM to 2 μM depending on the experiment), 20 μM lysine-63 linked or
lysine-48 linked diubiquitin with reaction cleavage buffer (50 mM Tris HCl pH 7.6, 50
mM NaCl, 1 mM DTT) at room temperature for 1 hour. The reactions were quenched
with 5X SDS buffer and the reactions were visualized by SDS-PAGE gel. Diubiquitin
was synthesized by Michael Sheedlo and Rashmi Shrestha.

2.4.3 Polyubiquitinated Green Fluorescent Protein Cleavage Assay
The polyubiquitinated Green Fluorescent Protein (GFP-UbN) substrate was
obtained from Michael Sheedlo from the Das lab who purified the GFP construct
containing a Rsp-5 binding motif (PY motif) and subsequently polyubiquitinating it using
previously published methods.5,6 Briefly, the GFP substrate containing the added PY
motif allows it to be recognized by Rsp5, an E3 ligase, and in conjunction with E1
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enzyme and Ubc4 (an E2 enzyme), the substrate is heterogeneously polyubiquitinated.
The initial assay was carried out as such: 50 nM of deubiquitinating enzyme and 2 μM of
GFP-UbN was incubated for 60 minutes on the benchtop at room temperature. Reactions
were quenched with 5X SDS buffer and subsequently run on an SDS-PAGE gel. For time
point assays, reactions were run at the same enzyme and GFP-UbN substrate for the
allotted time. Reactions were quenched with 5X SDS buffer, run on SDS-PAGE gels, and
the resulting reaction bands on the gels were quantified using ImageJ software.7

2.5 Crystallization of ChlaDub2
ChlaDub2 Δ93 crystallization was set up at ambient temperature using sitting drop
method. Initial crystallization screens were carried out at a concentration of 15 mg/mL
using Hampton Research crystallization screens. Crystals were further optimized using
the hit condition in addition to an additive screen (Hampton Research).
Crystals used in diffraction experiments at the Advanced Photon Source at
Argonne National Lab were soaked in 25% ethylene glycol (cryoprotectant) and liquid
nitrogen was used to flash freeze the crystal loop containing the Chladub2 Δ93 crystal.
HKL2000 software was used to process the diffraction data collected at the Advanced
Photon Source.8
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CHAPTER THREE. RESULTS AND DISCUSSION

3.1 Construct Design

3.1.1 Chlamydia Trachomatis Deubiquitinating Enzymes 2 Truncation Constructs
Since the previous study in 2006 by Hidde Ploegh’s lab characterizing the activity
of Chlamydia trachomatis Deubiquitinating Enzyme (ChlaDub2) was carried out using
whole cell lysates, the goal was to be able to clone and purify tractable constructs of
ChlaDub2. Specifically, these tractable constructs were to be able to be used for two
purposes: protein crystallography as well as for further biochemical characterization. To
achieve this goal, the sequence was analyzed using BioEdit software to confirm that a
hydrophobic region existed where there supposedly exists a 20 residue transmembrane
domain (Figure 3.1)
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Figure 3.1 Hydrophobicity plot of full-length ChlaDub2 generated with BioEdit

After confirming the presence of the hydrophobic region from residues 36 through 56, the
sequence of ChlaDub2 was inserted into a secondary structure prediction server,
PSIPRED Protein Sequence Analysis Workbench, to further refine our choices for
construct design (Figure 3.2).

Figure 3.2 Secondary structure prediction map using PSIPRED

While secondary structure prediction software is by no means absolute in its predictions,
it provided an initial idea of where truncations could be made. All three of the constructs
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to were cloned using pGEX-6P-1 vector to create N-terminal Glutathione-S-Transferase
(GST)-tagged proteins (Table 3.1) The last truncation construct to be cloned, ChlaDub2
Δ140 (residues 140-339) was cloned later after carrying out further biochemical assays.

Table 3.1 ChlaDub2 constructs.

As summarized in Table 3.1, four total truncation constructs were cloned and tested for
expression and solubility. Thought it was thought that the full-length construct would
prove to be difficult to work with due to the presence of the hydrophobic transmembrane
domain, we nevertheless carried out the cloning due to desiring a construct that would
encompass the entire protein and thus would preserve the entire secondary structure of
the protein. However, we found that the protein itself was insoluble in solution, even with
the GST-tag still attached to the protein (Appendix I). Since the full-length construct was
expected to not be tractable, ChlaDub2 Δ58 was cloned and expressed to have a construct
that would be the closest to a full-length protein. After expression and solubility, the Δ58
construct showed robust expression, as well as solubility. ChlaDub2 Δ93 showed both
robust expression as well as solubility and was chosen to further truncate the protein to
observe the minimal length of protein needed to maintain catalytic activity. The final
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truncation construct, ChlaDub2 Δ140, also showed robust expression; however, it showed
decreased solubility, especially in comparison to ChlaDub2 Δ58 and ChlaDub2 Δ93
(Appendix A). Additionally, ChlaDub2 Δ140 purification resulted in the protein crashing
out after cleavage of the N-terminal GST-tag. Thus, no further characterization was
carried out on the construct. However, based on the purification gel, the construct could
be studied in the future, provided that the protein is purified without cleaving the GSTtag (Appendix A).

3.1.2 ChlaDub2 Mutant Constructs
Mutagenesis of ChlaDub2 was carried out for proof of concept experiments to
reinforce that ChlaDub2 is indeed a cysteine protease. ChlaDub2’s catalytic triad consists
of histidine 203, aspartic acid 220, and the catalytic cysteine at residue position 282. Thus
the following mutagenesis were carried out: His203Ala, Asp220Asn, and Cys282Ala.
The aspartic acid and cysteine mutants were successful. However, within the time frame,
the histidine mutant was not mutated correctly.

3.1.3 Ubiquitin-Proparylamide Assay
The ubiquitin-propargylamide probe was used to test whether that the catalytic
triad of the cysteine protease is intact, due to the probe’s alkyne functionality forming a
covalent bond with the catalytic cysteine of Chladub2 (Figure 3.3) The experiment was
interpreted by observing whether an 8.5 kilodalton shift occurs between the ChlaDub2
construct at time zero and when the reaction was quenched. The 8.5 kilodalton shift
corresponds to the molecular weight of the ubiquitin-propargyl probe.
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Figure 3.3 Generalized ubiquitin-propargylamide reaction with cysteine protease
deubiquitinase. Blue circles represent ubiquitin (residues 1-75 with alkyne functionality)
and green quarter circles represent generalized cysteine protease DUB.

This assay was carried out specifically to show that the truncation constructs of
ChlaDub2 did not result in any interference with the catalytic activity of ChlaDub2.
Additionally, the assay was also done with the two mutant constructs to demonstrate the
success of the mutagenesis described in the previous section. As shown, both the
truncation constructs of ChlaDub2 showed a shift with the overnight reaction as
compared with the control lanes, thus showing that the catalytic activity was not
compromised by shortening the length of the protein. (Figure 3.4). Additionally, the
Cys282A showed no reaction, thus demonstrated the success of the mutagenesis, as well
as reinforcing that this enzyme is indeed a cysteine protease. (Figure 3.5). The
Asp220N’s reaction with the probe is not a surprising result as it was a conservative
mutation that was carried out and it is known that other DUBs can have an asparagine
residue in the active site in the place of aspartic acid.
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Figure 3.4 Reaction of 40 μM ChlaDub2 truncation constructs with excess ubiquitinpropargyl. A pipetting error was introduced into the assay in the control lane of
ChlaDub2 Δ58 construct, thus the protein not showing up at the same concentration as the
time 0 lane. Higher order bands in the ubiquitin-propargyl control lane, as well as time 0
lanes correspond to aggregation of the probe due to quenching by SDS buffer.
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Figure 3.5 Reaction of 40 μM ChlaDub2 mutant constructs and ChlaDub2 Δ58 control
with excess ubiquitin-propargyl. Higher order bands in the ubiquitin-propargyl control
lane, as well as time 0 lanes correspond to aggregation of the probe due to quenching by
SDS buffer. Asterisk indicates free GST contamination in sample

3.2 Biochemical Assays
3.2.1 Diubiquitin Cleavage Assays
A conventional way to demonstrate activity of deubiquitinating enzymes (DUBs)
is to carry out diubiquitin cleavage assays. Diubiquitin cleavage assays are a tractable
method that allow DUBs to be characterized in terms of figuring out their ubiquitin chain
preference, as well as determining kinetic parameters. This linkage was chosen to run for
the assay due to Lys-63 polyubiquitination being implicated in nuclear factor-κB signaling.
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Previous work implicated ChlaDub1 in decreasing ubiquitination of an nf-κB protein.
Therefore, we carried out an initial assay with ChlaDub2 Δ58 and ChlaDub2 Δ93 at a
concentration of 50 nM with 20 µM Lys-63 diubiquitin. (Figure 3.6) Additionally, SdeA,
a bacterial DUB derived from Legionella pneumophila, was run as a positive control due
to previous studies showing robust deubiquitination activity against Lys-63 diubiquitin.

Figure 3.6 Diubiquitin cleavage assay. 50 nM of of each deubiquitinating enzyme was
used. SdeA was used as a positive control against both ChlaDub2 constructs. 20 µM of
Lys-63 diubiquitin substrate was used for the reaction. The reaction was allowed to
proceed at room temperature for 60 minutes before being quenched.

The experiment here gave the impression that the protein was not as enzymatically robust
against diubiquitin. To make sure that the purified ChlaDub2 constructs were
enzymatically active, the diubiquitin cleavage assay was redone with higher ChlaDub2
enzyme concentration at 5 μM with the same substrate concentration and was run for 16
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hours total (Figure 3.7). Additionally, Lys-48 diubiquitin was also used in this
experiment to see if ChlaDub2 could cleave it in addition to Lys-63. The results of the
experiment demonstrate that at a higher enzyme concentration, ChlaDub2 is able to
cleave Lys-63 chains, in addition to Lys-48, due to complete cleavage of both chain types
overnight. However, even with the high enzyme concentration, it can be discerned that
ChlaDub2 prefers Lys-63 diubiquitin over Lys-48 diubiquitin due to a large amount of
monoubiquitin appearing at the 1 hour timepoint in the lanes corresponding to Lys-63.
Thus, it can be said that while the reaction doesn’t reflect physiologically relevant
parameters, some insight is given here that ChlaDub2 prefers Lys-63 linked diubiquitin
over Lys-48 linked diubiquitin.
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Figure 3.7 Diubiquitin cleavage assays with 5 μM ChlaDub2 and 20 μM diubiquitin.
Assays were run overnight with time-points taken at indicated times. (A) ChlaDub2 Δ58
diubiquitin cleavage assay. (B) ChlaDub2 Δ93 diubiquitin cleavage assay. Higher order
bands in the lanes corresponding to Lys-63 shows aggregation of the dibuiquitin substrate
due to being quenched with SDS buffer.
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3.2.2 Polyubiquitinated Green Fluorescent Protein Cleavage Assay
Another assay that was used to determine the activity and functional behavior of
ChlaDub2 was the polyubiquitinated Green Fluorescent Protein (GFP-UbN)
deubiquitination assay. The GFP substrate has a PY motif inserted which allows it to be
recognized by the WW domain of Rsp5, an E3 ubiquitin ligase enzyme.1,2 The
subsequent polyubiquitination of GFP-PY results in a heterogenous mixture of
polyubiquitin chains of different linkage types, lengths, and architectures on the lysine
residues of the GFP-PY substrate (Figure 3.8).

Figure 3.8 Representation of polyubiquitinated GFP-PY with heterogenous
mixture of Lys-11, Lys-48, Lys-63, and branched chain polyubiquitin covalently attached
to the substrate.

The initial GFP-UbN deubiquitination assay was carried out with ChlaDub2 Δ58,
ChlaDub2 Δ93, and SdeA as the positive control (Figure 3.9). The results of this assay
provided an interesting observation as the enzyme concentration as well as the time

41
needed for deubiquitination was markedly decreased compared to previously described
diubiquitin cleavage assays. The experiment was repeated at a higher DUB concentration
of 200 nM to potentially see a stronger laddering pattern (Figure 3.10). The results of this
experiment at 200 nM enzyme concentration gave the qualitative impression that the
Chladub2 Δ58 construct showed higher activity than the ChlaDub2 Δ93 construct. This
impression was ascertained due to the intensity of the laddering pattern on the gel, as well
as a less prominent smear being present at the top of the gel in the lanes corresponding to
ChlaDub2 Δ58. This result allowed us to consider using densitometry measurements with
ImageJ software to quantify the disappearance of the top GFP-UbN band. While no
specific kinetic parameters such as catalytic efficiency (Kcatt) or binding constant (KM)
can be determined through this assay due to the ubiquitin chains not being specific in
concentration, nonetheless, the relative activity of the protein can be probed. Using this
method with the two truncation constructs of ChlaDub2 would allow us to observe
whether the 35 residues between ChlaDub2 Δ58 and ChlaDub2 Δ93 aided in the protein’s
catalytic activity compared to each other. After running the experiment on an SDS-PAGE
gel, the laddering pattern revealed that different length ubiquitin chains are present.
However, information regarding the type of linkage was not available due to the
limitation of Coomassie Blue staining. Further studies could be carried out to determine
whether specific ubiquitin linkage chain types are more present than others in this assay.
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Figure 3.9 GFP-UbN Assay. Concentration of SdeA WT and ChlaDub2 constructs was 50
nM while the GFP-UbN substrate concentration was run at 2 μM.
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Figure 3.10 GFP-UbN assay with 200 nM ChlaDub2 enzyme concentration and 2 μM
GFP-UbN run for three hours at room temperature with timepoints taken every hour.
Polyubuiqitin chain species returned include diubiquitin (DiUb), triubiquitin (TriUb),
tetraubiquitin (TetraUb), and pentaubiquitin (PentaUb).

Using the results from the GFP-UbN assay with 200 nM of both constructs of
ChlaDub2, a time-point reaction was set up to observe deubiquitination activity of
ChlaDub2 Δ58. However, after running the experiment for two hours with time-points
taken every 20 minutes, the ImageJ quantification revealed that the signal was lost within
twenty minutes. The time and ChlaDub2 enzyme concentration was lowered to 50 nM for
a 1 hour reaction duration (Figure 3.11). This assay showed robust activity that the
protein exhibits within the first 10 minutes of the reaction. Due to the large decrease in
the intensity of the top band, the reaction was further optimized to take time points within
the first ten minute time frame. Observing that the reaction began to plateau after 30
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minutes, the reaction was carried out in triplicate for a duration of 32 minutes with the
following minute time-points: 0, 0.5, 1, 2, 4, 8, 16, 32 (Figure 3.12, Figure 3.13). The two
constructs of the enzymes compared to each other exhibit relatively the same activity, as
the time to deubiquitinate half the 2 uM GFP-UbN substrate is roughly 4 minutes for each
construct (Figure 3.14). The level of error in this assay, especially in the experiment
corresponding to ChlaDub2 Δ58, is reflective of variability in staining and destaining the
SDS-PAGE gels. However, since the goal of the experiment was to determine relative
activity and not give specific kinetic parameters, the assay can further be optimized to
lessen the error.
The same GFP-UbN deubiquitination reaction with 50 nM ChlaDub2 enzyme
concentration and 2 μM was carried out with non-polyubiquitinated GFP run as a control
(Figure 3.15, Figure 3.16). Non-polyubiquitinated GFP returned by 8 minutes, thus
implying that the concentration of non-polyubiquitinated GFP was high enough between
the 4 and 8 minute window. This can be inferred due to the previous GFP-UbN
quantification experiments showing that relatively half of the substrate was
deubiquitinated by the 4 minute time point.
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Figure 3.11 Quantification of disappearance of polyubiquitinated GFP. The top band of
the gel shows the presence of GFP-UbN. The plot to the right of the gel shows the
quantification of the disappearance of GFP-UbN at ten minute time points. No signal was
able to be picked up after 40 minutes and thus was not plotted.

Figure 3.12 Quantification of the disappearance of polyubiquitinated GFP top band of
ChlaDub2 Δ58. ChlaDub2 concentration was 50 nM and GFP-UbN concentration was 2
µM. Reaction was carried out for 32 minutes duration with time-points being taken at
indicated times.
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Figure 3.13 Quantification of the disappearance of polyubiquitinated GFP top band of
ChlaDub2 Δ93. ChlaDub2 concentration was 50 nM and GFP-UbN concentration was 2
µM. Reaction was carried out for 32 minutes total with time points being taken at
indicated times.

Figure 3.14 Comparison plot of GFP deubiquitination by ChlaDub2 Δ58 and ChlaDub2
Δ93. Plots of the quantification of the top band in each GFP-UbN assay here were plotted
against each other to directly compare activity.
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Figure 3.15 GFP-UbN deubiquitination assay with 50 nM ChlaDub2 Δ58 and 2 μM GFPUbN with non-polyubiquitinated GFP run as a control.

‐
Figure 3.16 GFP-UbN deubiquitination assay with 50 nM ChlaDub2 Δ93 and 2 μM GFPUbN with non-polyubiquitinated GFP run as a control
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The quantification of the disappearance of the top band corresponding to the
polyubiquitinated GFP shows that both truncation constructs used in this study,
ChlaDub2 Δ58 and ChlaDub2 Δ93, exhibit generally the same rate of enzymatic activity,
thus ChlaDub2 Δ93 seems to be a suitable minimal catalytic construct. The GFP-UbN
experiments also provide interesting results regarding the functional behavior of
ChlaDub2, especially when compared with the results of the diubiquitin cleavage assays.
Since the heterogenous array of polyubiquitinated chains on the GFP substrate contains a
mixture of mainly Lys-63 polyubiquitin chains with a smaller proportion Lys-11, Lys-48,
and branched chain ubiquitin, there exist two different possible explanations for
potentially elucidating ChlaDub2’s mechanism in this assay.1 The first scenario may be
that Chladub2 has a preference for longer Lys-63 polyubiquitin chains. This seems
reasonable as it is unlikely that Rsp5 would make long branched chains, nor would it
make large populations of Lys-11 and Lys-48 linked polyubiquitin chains compared to
Lys-63 linked polyubiquitin. Additionally, as shown above with the diubiquitin cleavage
assay, though ChlaDub2’s enzymatic activity on diubiquitin is not at all robust,
nonetheless the enzyme shows a preference for Lys-63 over Lys-48. Physiologically, this
preference for Lys-63 polyubiquitin likely reflects ChlaDub2’s role as a bacterial effector
in helping Chlamydia.trachomatis (C. trachomatis) evade the host cell’s immune
response. Firstly, deubiquitination of Lys-63 polyubiquitin would protect the C.
trachomatis vacuole from lysosomal degradation. Secondly, perhaps ChlaDub2 may also
protect against the inflammatory response as ChlaDub1 has been shown to do in a
previous study.5 Perhaps the two deubiquitinating enzymes work in tandem or may each
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have a specific functional niche within the context of protecting the infectious C.
trachomatis from degradation by the host cell.
The second potential scenario is that ChlaDub2’s enzymatic activity may be
enhanced due to the ubiquitin chains being anchored to a protein substrate (in this case,
GFP). This polyubiquitinated substrate mimics a more physiologically relevant substrate,
though it should be noted that GFP is a generic substrate used for this assay and not the
actual physiological substrate of ChlaDub2. The protein’s activity in this assay may be
mimicking its function in the cell by interacting with anchored polyubiquitin chains. By
half of the substrate population being deubiquitinated within the 4 to 8 minute time frame
may indicate that the enzyme may interact with the protein and cleave off whole chains
off the substrate. Additionally, as shown in the experiment where the enzyme
concentration was run at 200 nM for 3 hours, there exists a diverse laddering pattern
indicating different lengths of ubiquitin chains. At this high enzyme concentration and
longer reaction time, it may indicate that the protein prefers longer chains attached to a
substrate, but does not cleave chains as efficiently once they are cleaved off the substrate.
Additionally, since diubiquitin appears to be the smallest product returned in this assay at
200 nM, this reinforces the observation that smaller chains are not optimal for cleavage
by the enzyme. To further determine whether this scenario is plausible, further studies
would need to be carried out by changing the model substrate to ensure that the GFP
protein itself is not contributing to ChlaDub2’s activity in this assay.
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3.3 Crystallization
The ChlaDub2 Δ93 construct was set up on crystallization trays due to the
purification yielding a more pure sample compared to ChlaDub2 Δ58. Crystal screens
were set up using screens from Hampton Research, including PEG/ION I &2, Crystal
Screen I &2, and Grid Screen Ammonium Sulfate. An initial hit was found in Crystal
Screen I with the following condition: 0.1 M HEPES Sodium pH 7.5, 2% (v/v)
polyethylene glycol (PEG)-400, 2 M ammonium sulfate. The initial hit yielded small
spherical crystals that did not look suitable for diffraction (Figure 3.17).

Figure 3.17 Preliminary crystals and crystallization condition information. Crystallization
condition originated from Crystal Screen I (Hampton Research)

Crystals were then further optimized by first recreating the initial hit using a
crystallization condition that was made using lab reagents rather than a premade
condition from Hampton Research. Once crystallization was replicated with crystals that
looked like the initial hit, an additive screen (Hampton Research) was carried out. This
screen consisted of using the initial crystallization condition hit and adding different
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types of reagents that would aid in solubility and crystallization of protein. After six days,
a hit was found in the condition containing N-sulfobetaine, an ionic detergent. The
crystals appeared to possess a single lattice and looked suitable for diffraction. Thus, the
crystals were looped, dipped in 25% ethylene glycol cryoprotectant, and flash frozen
using liquid nitrogen. The crystal was mounted at the Advanced Photon Source at
Argonne National Lab and showed diffraction resembling a protein crystal. Rastering was
carried out on the crystal to determine the optimal area to direct the X-ray beam to collect
a diffraction pattern and subsequent data set (Appendix A). A dataset was collected and it
was determined that the crystal diffracted to 2.3 Å (Figure 3.18, Table 3.2).

Figure 3.18 Diffraction pattern of ChlaDub2 Δ93 crystallized in 0.1 M HEPES Sodium
pH 7.5, 2% (v/v) PEG-400, 2 M Ammonium Sulfate
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After processing the data using HKL2000 software at the Advanced Photon
Source, it was determined that the protein crystal exhibited orthorhombic symmetry and
was processed in P222, P2221, P21212, and P212121 space groups. Using Phaser, a
crystallographic software, the space group was determined to be P212121. Structure
determination began by using molecular replacement in an attempt to phase the structure.
A model was made using the SWISS-MODEL server, the model that was generated was
based off of sentrin-specific protease 1 (SENP1), a human enzyme that cleaves small
ubiquitin-like modifier (SUMO) off target proteins (Figure 3.19). The sequences between
ChlaDub2 and SENP1 share 18.69 percent sequence similarity and had the highest
sequence homology based on protein structures deposited in the Protein Data Bank
database. The model of ChlaDub2 based off of SENP1 shows a mixed beta-sheet
consisting of three stands nestled against an alpha-helix, which is reminiscent of the ULP
domain core folds.3,4 The molecular replacement was carried out using Phaser and went
through structure refinement to generate an electron density map. After multiple rounds
of refinement, the electron density map was essentially uninterpretable in that secondary
structure was not discernable. The final Rwork and Rfree values that were generated after
these multiple rounds of structure refinement were 0.548 and 0.536 respectively. Further
structural refinement resulted in the values remaining stagnant and not lowering. Thus,
based on these statistical values, though SENP1 had the highest sequence homology to
ChlaDub2, using it as a model did not allow ChlaDub2’s structure to be phased with the
dataset that was collected.
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Figure 3.19 Model of ChlaDub2 used in molecular replacement based off of SENP1.
Model based off of PDB code 2CKG
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Table 3.2 Crystallographic parameters summary of ChlaDub2 Δ93. * indicates value in
highest resolution shell

3.4 Future Directions
A structure of ChlaDub2 would prove beneficial, both in elucidating the structure
itself, as well as giving insight into how the enzyme functions in regards to its
deubiquitinating activity. In order to phase the ChlaDub2 Δ93 apo structure,
selenomethionine labeling of the ChlaDub2 construct would give further chances for the
structure to be phased successfully (Appendix A). Additionally, biochemical function of
the enzyme could potentially be gleaned by co-crystallization of the Cys282A mutant
with diubiquitin. This structure would provide insight into how diubiquitin interacts with
the protein in terms of binding in the active site as well as any other protein-protein
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interactions. Additionally, an ubiquitin-propargyl crystal structure would also provide
insight regarding the interactions between ubiquitin and the active site of ChlaDub2.
Furthermore, to show a preference for higher order ubiquitin chains, triubiquitin
and tetraubiquitin chains could be synthesized and then tested against ChlaDub2 in the
same manner as diubiquitin was run in this study. This would provide further evidence
whether ChlaDub2 actually prefers long polyubiquitin chains, especially when compared
against diubiquitin substrates. Additionally, isothermal titration calorimetry could be
carried out with ubiquitin and diubiquitin especially to determine the dissociation
constant with ChlaDub2. By determining this value, perhaps some insight could be
gained into why diuibiquitin cleavage is not as robust. Lastly, to further probe the idea
that polyubuiqitin chains anchored to a substrate are optimal for ChlaDub2’s enzymatic
activity, the same activity assay could be carried out, but with a different substrate such
as Sic1 which has been previously purified and subsequently polyubiquitinated in the Das
lab using previously published methods.6
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APPENDIX

Figure A1 Expression and Solubility of ChlaDub2 Δ93

Figure A2 Purification of ChlaDub2 Δ93
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Figure A3 Cloning of ChlaDub2 Δ140. After overnight ligation, colony PCR was
carried out confirm colonies contained Δ140 insert in pGEX-6P-1

Figure A4 Purification of ChlaDub2 Δ140
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Figure A.5 Rastering of crystal mounted on beam at Advanced Light Source at
Argonne National Lab.

60

Figure A.6 Purification of SeMet ChlaDub2 Δ93

